TY - JOUR
T1 - COVID-19 severity and vaccine breakthrough infections in idiopathic inflammatory myopathies, other systemic autoimmune and inflammatory diseases, and healthy controls :
T2 - a multicenter cross-sectional study from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) survey
AU - Hoff, Leonardo Santos
AU - Ravichandran, Naveen
AU - Shinjo, Samuel Katsuyuki
AU - Day, Jessica
AU - Sen, Parikshit
AU - Junior, Jucier Gonçalves
AU - Lilleker, James B.
AU - Joshi, Mrudula
AU - Agarwal, Vishwesh
AU - Kardes, Sinan
AU - Kim, Minchul
AU - Milchert, Marcin
AU - Makol, Ashima
AU - Gheita, Tamer
AU - Salim, Babur
AU - Velikova, Tsvetelina
AU - Gracia-Ramos, Abraham Edgar
AU - Parodis, Ioannis
AU - Selva O'Callaghan, Albert
AU - Nikiphorou, Elena
AU - Tan, Ai Lyn
AU - Chatterjee, Tulika
AU - Cavagna, Lorenzo
AU - Saavedra, Miguel A.
AU - Ziade, Nelly
AU - Knitza, Johannes
AU - Kuwana, Masataka
AU - Nune, Arvind
AU - Distler, Oliver
AU - Cansu, Döndü Üsküdar
AU - Traboco, Lisa
AU - Wibowo, Suryo Angorro Kusumo
AU - Tehozol, Erick Adrian Zamora
AU - Serrano, Jorge Rojas
AU - La Torre, Ignacio García-De
AU - Wincup, Chris
AU - Pauling, John D.
AU - Chinoy, Hector
AU - Agarwal, Vikas
AU - Aggarwal, Rohit
AU - Gupta, Latika
PY - 2022
Y1 - 2022
N2 - We aimed to compare the spectrum and severity of COVID-19 and vaccine breakthrough infections (BIs) among patients with IIMs, other systemic autoimmune and inflammatory diseases (SAIDs), and healthy controls (HCs). This is a cross-sectional study with data from the COVAD study, a self-reported online global survey that collected demographics, COVID-19 history, and vaccination details from April to September 2021. Adult patients with at least one COVID-19 vaccine dose were included. BIs were defined as infections occurring > 2 weeks after any dose of vaccine. Characteristics associated with BI were analyzed with a multivariate regression analysis. Among 10,900 respondents [42 (30-55) years, 74%-females, 45%-Caucasians] HCs were (47%), SAIDs (42%) and IIMs (11%). Patients with IIMs reported fewer COVID-19 cases before vaccination (6.2%-IIM vs 10.5%-SAIDs vs 14.6%-HC; OR = 0.6, 95% CI 0.4-0.8, and OR = 0.3, 95% CI 0.2-0.5, respectively). BIs were uncommon (1.4%-IIM; 1.9%-SAIDs; 3.2%-HC) and occurred in 17 IIM patients, 13 of whom were on immunosuppressants, and 3(18%) required hospitalization. All-cause hospitalization was higher in patients with IIM compared to HCs [23 (30%) vs 59 (8%), OR = 2.5, 95% CI 1.2-5.1 before vaccination, and 3 (18%) vs 9 (5%), OR = 2.6, 95% CI 1.3-5.3 in BI]. In a multivariate regression analysis, age 30-60 years was associated with a lower odds of BI (OR = 0.7, 95% CI 0.5-1.0), while the use of immunosuppressants had a higher odds of BI (OR = 1.6, 95% CI 1.1-2.7). Patients with IIMs reported fewer COVID-19 cases than HCs and other SAIDs, but had higher odds of all-cause hospitalization from COVID-19 than HCs. BIs were associated with the use of immunosuppressants and were uncommon in IIMs. The online version contains supplementary material available at 10.1007/s00296-022-05229-
AB - We aimed to compare the spectrum and severity of COVID-19 and vaccine breakthrough infections (BIs) among patients with IIMs, other systemic autoimmune and inflammatory diseases (SAIDs), and healthy controls (HCs). This is a cross-sectional study with data from the COVAD study, a self-reported online global survey that collected demographics, COVID-19 history, and vaccination details from April to September 2021. Adult patients with at least one COVID-19 vaccine dose were included. BIs were defined as infections occurring > 2 weeks after any dose of vaccine. Characteristics associated with BI were analyzed with a multivariate regression analysis. Among 10,900 respondents [42 (30-55) years, 74%-females, 45%-Caucasians] HCs were (47%), SAIDs (42%) and IIMs (11%). Patients with IIMs reported fewer COVID-19 cases before vaccination (6.2%-IIM vs 10.5%-SAIDs vs 14.6%-HC; OR = 0.6, 95% CI 0.4-0.8, and OR = 0.3, 95% CI 0.2-0.5, respectively). BIs were uncommon (1.4%-IIM; 1.9%-SAIDs; 3.2%-HC) and occurred in 17 IIM patients, 13 of whom were on immunosuppressants, and 3(18%) required hospitalization. All-cause hospitalization was higher in patients with IIM compared to HCs [23 (30%) vs 59 (8%), OR = 2.5, 95% CI 1.2-5.1 before vaccination, and 3 (18%) vs 9 (5%), OR = 2.6, 95% CI 1.3-5.3 in BI]. In a multivariate regression analysis, age 30-60 years was associated with a lower odds of BI (OR = 0.7, 95% CI 0.5-1.0), while the use of immunosuppressants had a higher odds of BI (OR = 1.6, 95% CI 1.1-2.7). Patients with IIMs reported fewer COVID-19 cases than HCs and other SAIDs, but had higher odds of all-cause hospitalization from COVID-19 than HCs. BIs were associated with the use of immunosuppressants and were uncommon in IIMs. The online version contains supplementary material available at 10.1007/s00296-022-05229-
KW - Autoimmune diseases
KW - Breakthrough infection
KW - COVID-19
KW - Idiopathic inflammatory myopathies
KW - SARS-CoV-2 vaccination
U2 - 10.1007/s00296-022-05229-7
DO - 10.1007/s00296-022-05229-7
M3 - Article
C2 - 36271958
SN - 0172-8172
SP - 1
EP - 12
JO - Rheumatology International
JF - Rheumatology International
ER -
